Navigation Links
Europe-wide investment in lipid research will help tackle disease, says new report
Date:6/16/2008

Leading scientists today called for Europe to invest more funds into the study of lipids the 'fatty' molecules that play a crucial role in the function of human cells and which are implicated in a range of diseases from obesity and diabetes to Alzheimer's.

Common lipids such as cholesterol are known to play an important part in the normal functioning of cells and tissues, but human cells contain thousands of different lipids which are also vital for functions that include storing energy, maintaining the structure of the cell and sending biochemical signals. Scientists are discovering that if the biochemical pathways that regulate the metabolism and transport of these lipids become disturbed, this can result in disease.

A report* published today by the European Science Foundation (ESF) urges greater cooperation among researchers and more investment in the field of 'lipidomics' the term given to the identification and analysis of the full complement of lipids in cells, tissues and body fluids, together with associated molecular structures such as enzymes and genes. The document is the output of a science policy activity led by the European Medical Research Councils (EMRC), the medical section within ESF.

The ESF science policy briefing document, drawn up by an international panel of experts led by Professor Gerrit van Meer of Utrecht University in The Netherlands and Professor Friedrich Spener of the University of Graz in Austria, says that the study of lipids has been largely neglected because until recently technology did not exist to analyse this complex class of molecules comprehensively. However, the application of an analytical technique called mass spectrometry now allows large numbers of lipids to be analysed rapidly. "This remarkable technological breakthrough will make it possible to better understand the cellular machineries that are responsible for producing and storing energy in cells, for the transport across and between
'/>"/>

Contact: Professor Gerrit van Meer
g.vanmeer@uu.nl
31-302-533-427
European Science Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Sanitation investment in poor countries would yield $9-to-1 benefits in productivity, health: UN
2. New genetic variants associated with lipid levels, risk for coronary artery disease
3. Story ideas from the Journal of Lipid Research
4. Lipids in the brain an important factor for Alzheimers disease?
5. Story ideas from the Journal of Lipid Research
6. Powerful integration of lipid metabolic profiling with gene expression analysis
7. Chemists get grip on slippery lipids
8. Story ideas from the Journal of Lipid Research
9. Stem cell researchers give old muscle new pep
10. UT Southwestern researchers create molecule that nudges nerve stem cells to mature
11. Growing use of nanomaterials spurs research to investigate possible downsides

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e course of a lifetime, the heart pumps some 250 m...der to do this, the muscle fibers of the heart hav...ed by Dr. Wolfgang Rottbauer, vice chair of the De...Hospital (Chairman: Prof. Dr. H. A. Katus), has di...bility of the smallest muscular unit, the sarcomer...
(Date:11/24/2009)...us Research Institute (LRI) today named 12 new gra...million, recognize innovative work across a broad ...their creativity, novelty, and potential to drive ... and cure the complex disease of systemic lupus. ,...lupus researchers across the nation and include in...
(Date:11/24/2009)...mic-level action of a remarkable class of ring-sha...rs with the Lawrence Berkeley National Laboratory ...ystallography beamline at the Advanced Light Sourc...n gene expression and replication, and are vital t... infectious agents, such as the human papillomavir...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4NIMBioS hosts tutorial on optimal control and optimization for biologists 10071 1New Parkinsons Drug Draws Mixed Reviews 58192 1New Parkinsons Drug Draws Mixed Reviews 58192 2New Parkinsons Drug Draws Mixed Reviews 58192 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3
..., , Svilen Bobev, assistant professor of chemistry...ce Foundation,s prestigious Faculty Early Career D...g award, designed to support the integrated resear...their careers, is bestowed on those scientists and...ic leaders of the 21st century. Fewer than 20 perc...
..., Researchers from the University of North Caroli...mechanism that may account for the development of ...e born with in the US every year. The findings, p...oS Computational Biology, add new knowledge to und... also point the way to new corrective treatments. ...
..., NEW YORK (Feb. 28, 2007) -- The general public ...ase (CKD) is a serious and progressive medical con...ed. Understandably so, since in its early stages C...the disease and their health-care providers unawar...r, if CKD is detected and treated early, its wides...
Other Biology News:UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 2UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 3Computer simulations point to key molecular basis of cystic fibrosis 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 3Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 4
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced the approval of...ptcy Court for the District of Delaware,(the "Bank... petition for,relief under Chapter 11 of the Unite.... , The orders issued by the Bankruptcy C...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/...ood & Drug Administration (SFDA) has approved ... its oral insulin project,(Nodlin), an innovative ...proval allows Biolaxy to initiate its first phase ...r characteristic of high blood glucose and poor,me...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met... endometrial cancer, , QUEBEC CITY, Nov. 24 /...DAQ: AEZS ; TSX: AEZ) (the "Company"), a global b...apy and oncology, today announced positive efficac...toxic peptide conjugate, AEZS-108 (formerly AN-152...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fir...RNA ) announced today that the company is schedu...alth Care Conference on December 1, 2009 at 11:30 ...New York Palace Hotel in New York City. Jack Lief,... scheduled to provide an overview of the company, ...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... Integrated Global Services, CAMBRIDGE, Mass., Ap...launches under a new name, Abt Bio-Pharma Solution...es Inc. The company will continue to,provide custo...for the,pharmaceutical, biotechnology, medical dev...proach that blends decades of experience with wide...
...08 Cardium Therapeutics,(Amex: CXM ) and its ope...at,InnerCool has entered into a European commercia...Euromed), a leading distributor of cardiology,medi...romed will have,exclusive marketing, sales and dis...nd for InnerCool,s portfolio of temperature modula...
... 1, 2008 Derma Sciences,Inc (OTC Bulletin Board: ...reported that sales for 2007 were $34.1 million, a...ported for 2006. Gross margins held steady at 34,p... in new products for the,pipeline, and expanding t...ny reported a loss of $2.3 million or $0.09 loss p...
Other Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
T4 Polynucleotide Kinase Exchange Reaction Buffer from Invitrogen
IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
FlowTACS Flow Cytometry Apoptosis Detection Kit from R&D Systems
Biology Products: